patents Archives | BioInformant

30 Key Patents about Cord Blood (UPSTO)

December 13, 2016 By Cade Hildreth (CEO) Leave a Comment

A crucial benchmark to track for the cord blood market is the number and type of cord blood related patents that have been issued.

The United States Patent and Trademark Office (USPTO) has a patent analysis tool that offers a “Full Text and Image Database Search.” The database includes information about all American patents, from the first patent issued in 1790 to the most recent issue week.¹ The text of patents issued from January 1976 to the present is fully searchable, including bibliographic data, such as the inventor’s name, the patent’s title, and the assignee’s name; the abstract; the full description of the invention; and the claims.² [Read more…]

Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells

September 19, 2016 By Cade Hildreth (CEO) Leave a Comment

Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI

RANCHO CORDOVA, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca’s proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). [Read more…]

Historic Patent Challenges to Pluripotent Stem Cells (ESCs and iPSCs)

June 22, 2016 By Cade Hildreth (CEO) Leave a Comment

Two of the most versatile and powerful pluripotent stem cell types are embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). For this reason, the patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial purposes.

The most infamous stem cell patents are held by the Wisconsin Alumni Research Foundation (WARF) and concern the derivation of human embryonic stem cells (hESCs). Founded in 1925, the Wisconsin Alumni Research Foundation (WARF) is a nonprofit patent and licensing organization for the University of Wisconsin–Madison.” It manages a $2.6 billion endowment build over 90 years of licensing activity , making it one of the world’s most successful university-based technology transfer offices. [Read more…]

Pluristem Fortifies IP Position and Partnering Potential in Japan with Two Key Cell Therapy Patents

April 13, 2016 By Cade Hildreth (CEO) Leave a Comment

In major news released today, Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. Pluristem Therapeutics is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

Therefore, the patents pertain to the three-dimensional growth of placental and fat cells and the use of placental cells grown with 3D technology:

Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”

To learn more about the company, see our recent interview Dr. Racheli Ofir, VP Research & Intellectual Property for Pluristem Therapeutics. Or, read the full press release below, printed with permission from Dr. Ofir. [Read more…]

iPSC Market: 3 Major Market Forces (and Why You Should Care) | Infographic

January 11, 2015 By Cade Hildreth (CEO) 1 Comment

The induced pluripotent stem cell (iPSC) market first emerged in 2006, when iPSC technology was pioneered by Shinya Yamanaka’s lab at Kyoto University in Japan. The shocking discovery that the introduction of four transcription factors into adult cells could convert them into pluripotent stem cells sent waves of excitement throughout the scientific community.

This landmark event came to represent one of the greatest stem cell research discoveries of all time and was memorialized in 2012, when Dr. Yamanaka and Sir John Gurdon were awarded the Nobel Prize “for the discovery that mature cells can be reprogrammed to become pluripotent.”

iPSC technology has since revolutionized how stem cells are derived, differentiated, and acquired in industrial quantities. It has also dramatically affected our understanding of how human cells and organisms develop.
[Read more…]

Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI

BioInformant's World-Class Clients